More tools:Markets·Screener·Research·Chat

Kalaris Therapeutics, Inc. Common Stock (KLRS) Financial Statements

Kalaris Therapeutics, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00P80SH43
XNAS · usd
3.60▼ 0.03 (-0.83%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close3.63
Day's Range3.60 – 3.90
52-Week Range3.03 – 11.88
Volume100.7K
Avg Volume59.5K
Share Statistics
Shares Outstanding
Employees20
ExchangeXNAS
Listed2025-03-19
Share count as of August 4, 2026
Loading Income Statement…
Key questions about Kalaris Therapeutics, Inc. Common Stock (KLRS)
What is Kalaris Therapeutics, Inc. Common Stock's Market Cap?
Kalaris Therapeutics, Inc. Common Stock's Market Cap is $85.7M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Enterprise Value?
Kalaris Therapeutics, Inc. Common Stock's Enterprise Value is -$7.8M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's EV / EBITDA?
Kalaris Therapeutics, Inc. Common Stock's EV / EBITDA is 0.2×, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Net Income (TTM)?
Kalaris Therapeutics, Inc. Common Stock's Net Income (TTM) is -$44.3M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's EBITDA?
Kalaris Therapeutics, Inc. Common Stock's EBITDA is -$47.7M, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Kalaris Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -1.86, based on as-reported figures from SEC (XBRL) filings.
What is Kalaris Therapeutics, Inc. Common Stock's Net Debt?
Kalaris Therapeutics, Inc. Common Stock's Net Debt is -$93.5M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development (including $15, $12, $30 and $25 for a related party)
General and administrative (including $93, $37, $160 and $188 for a related party)
Total operating expenses
Loss from operations
Other income (expense), net:
Change in fair value of tranche liability (including $0, $0, $0 and $331 for a related party)
Change in fair value of derivative liabilities (including $0, $0, $0 and $1,165 for a related party)
Interest expense (including $0, $0, $0 and $1,384 for a related party)
Loss on extinguishment and on issuance of convertible promissory notes (including $0, $0, $0 and $169 for a related party)
Other income, net
Total other income, net
Net loss
Net loss per share attributable to common stockholders - basic
Net loss per share attributable to common stockholders - diluted